Tissue Engineering

13.5% Global CAGR for Tissue Engineering Market Market to achieve US$ 25,586.55 Mn by 2027

Medtronic & Zimmer Biomet-Notable Market Players in Tissue Engineering Market

Tissue engineering is a technique, which is used as a combination of material methods and cells. Also, this technique follows the physicochemical and biochemical factors to replace and improve the biological tissues. It is an exciting strategy that works on the scaffolds, stem cells, regenerative medicine and growth factors or negotiators either in isolation or in combination. The technique uses molecular and cellular methods to combine with material engineering principles to restore tissue surgically.

Market leaders operating in the market have undertaken various organic growth strategies in the tissue engineering market. The tissue engineering market majorly consists of the players such as Stryker Corporation, Organogenesis Inc., Cook Biotech Inc., Integra Life Sciences Corporation, Acelity L.P.Inc, Allergan Plc., Medtronic, Zimmer Biomet, Baxter International Inc. and DePuy Synthes (Johnson & Johnson Services, Inc.) and others. Several organic approaches, such as product launches, and expansion in the tissue engineering market, have resulted in the positive growth of the market. Product launches help the company to strengthen its product offering and the customer base, which allows the company to hold a strong position in the market. Similarly, utilizing expansion activities, it is easy to venture into untapped economies and use the opportunities being offered.

Below is the list of the growth strategies done by the players operating in the tissue engineering market:




Integra LifeSciences Holdings Corporation, announced the recent approval of DuraGen Dural Regeneration Matrix in Japan. DuraGen is the first and only non-autologous collagen xenograft approved for use as a dural substitute in Japan.


Medtronic plc announced it has received FDA approval of Infuse Bone Graft for new spine surgery indications.


Baxter International Inc. announced U.S. Food and Drug Administration (FDA) clearance of ALTAPORE Bioactive Bone Graft, a next-generation bioactive and osteoconductive bone graft substitute, for use as an autograft extender in posterolateral spinal fusion.



Leave a Reply

Your email address will not be published. Required fields are marked *